We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Collaboration to Develop Diagnostic Test for Purpura

By Labmedica staff writers
Posted on 07 Dec 2006
Ciphergen (Fremont, California, USA) and Ohio State University Research Foundation (OSURF, Columbus, OH, USA) have announced a collaborative agreement to develop and clinically validate a diagnostic test to detect thrombotic thrombocytopenic purpura (TTP), a hematologic disease. More...


Under the terms of the agreement, OSURF and Ciphergen will optimize the assay to measure enzyme and antibody inhibition activity, and will jointly conduct multi-center studies to validate the test. Financial terms of the agreement were not disclosed.

TTP is a blood disorder characterized by low platelets, low red blood cell count (caused by premature breakdown of the cells), neurologic abnormalities, and sometimes abnormalities in kidney function. In most cases, this disease is caused by a deficiency in auto-antibodies to an enzyme called a disintegrin and metalloproteinase with a thrombospondin type 1 motif 13 (ADAMTS-13). Loss of this enzyme causes platelet clumping and red blood cell destruction.

"A clinical diagnostic test that can rapidly detect deficiencies in the enzyme activity associated with TTP will help physicians more effectively manage this devastating disease,” said Haifeng M. Wu, M.D., assistant professor of pathology and medicine and director of the clinical coagulation laboratory at Ohio State University Medical Center. "This test will help physicians determine when to initiate plasma exchange and monitor response to this therapy.” Working with Dr. Wu, Ciphergen intends to optimize a surface-enhanced laser desorption/ionization (SELDI)-based test, which will be reproducible and will accurately measure the product of the enzymatic reaction that underlies this disease.

Annual testing opportunities are needed to diagnose patients with TTP, evaluate patient responses to therapy, and monitor patients during clinical remission to prevent recurrences of the disease.

Ciphergen Biosystems is dedicated to the discovery, development, and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat, and improve outcomes for patients. The company has ongoing diagnostic programs in oncology/hematology, cardiology, and women's health with a focus on ovarian cancer.



Related Links:
Ciphergen
Ohio State University Research Foundation

Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
New
Repetitive Pipette
VWR® Stepper Pro
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The findings suggest that people with mpox can transmit the virus even without clinical symptoms (image credit: Adobe Stock)

Study Finds Hidden Mpox Infections May Drive Ongoing Spread

Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.